Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Africa Proposes Joint Coronavirus Clinical Trial Reviews

IP Relaxations Also Urged By UN Body

Executive Summary

After a slow start, the coronavirus is now taking hold in Africa, with almost all of the continent's 54 countries reporting cases of infection. Actions being taken to tackle the disease include cooperation on speeding up the approval of coronavirus clinical trials, while a report from the UN says coordinated efforts on the distribution of medical supplies are needed.

You may also be interested in...



African Countries Urged To Back New Medicines Agency

COVID-19 has highlighted the need for greater harmonization of medicines regulation to tackle health issues and emergencies more effectively in Africa. With that in mind, countries are being encouraged to speed up their ratification of a treaty setting up a new pan-African body tasked with coordinating national regulatory efforts, improving access to quality medicines and supporting the local pharmaceutical industry.

New Deal To Boost Progress On African Medicines Agency

A new agreement between the WHO and the African Union is expected to strengthen efforts to create the new African Medicines Agency, following the endorsement of the AMA treaty earlier this year.

UK Spending £2.9bn On Seven COVID-19 Vaccines

The UK government says it is on track to vaccinate the 15 million most vulnerable people by mid-February, and that a “major study” is under way to assess the potential impact of the new UK variant on vaccine efficacy.

Topics

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel